Fig. 7.
Intranasal administration of RvE1 produces antidepressant-like actions via BDNF/VEGF release in the dorsal DG in LPS-induced depression model mice. a Experimental timeline for LPS challenge (0.8 mg/kg, i.p.), intra-DG infusion of either control IgG (200 ng/side) or BDNF nAb (200 ng/side), i.n. administration of either vehicle (0.5% ethanol/PBS) or RvE1 (10 ng/mouse), and behavioral testing. b Effects of intra-DG infusion of BDNF nAb and i.n. administration of RvE1 on LMA in LPS-challenged mice (interaction, F1,19 = 1.66, p = 0.213; BDNF nAb, F1,19 = 0.539, p = 0.472; RvE1, F1,19 = 1.88, p = 0.186). c, d Effects of intra-DG infusion of BDNF nAb on the antidepressant-like actions of i.n. administration of RvE1 in the TST (c, interaction, F1,18 = 9.79, p = 0.0058; one IgG + RvE1-treated mouse was excluded due to tail-climbing) and FST (d, interaction, F1,19 = 6.22, p = 0.0221) in LPS-challenged mice. e Schematic representation of the DG infusion sites. Plates are from ref. 36. f Experimental timeline for LPS challenge, intra-DG infusion of either control IgG (80 ng/side) or VEGF nAb (80 ng/side), i.n. administration of either vehicle or RvE1, and behavioral testing. g Effects of intra-DG infusion of VEGF nAb and i.n. administration of RvE1 on LMA in LPS-challenged mice (interaction, F1,22 = 0.121, p = 0.731; VEGF nAb, F1,22 = 0.633, p = 0.435; RvE1, F1,22 = 0.736, p = 0.400). h, i Effects of intra-DG infusion of VEGF nAb on the antidepressant-like actions of i.n. administration of RvE1 in the TST (h, interaction, F1,21 = 20.5, p = 0.0002; one VEGF nAb + RvE1-treated mouse was excluded due to tail-climbing) and FST (i, interaction, F1,22 = 11.7, p = 0.0025) in LPS-challenged mice. j Schematic representation of the DG infusion sites. Plates are from ref. 36. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Holm-Sidak’s post hoc test)